恩度与化疗联合治疗非小细胞肺癌疗效观察

Clinical study of chemotherapy combined with endostar in the treatment of advanced non-small cell lung cancer

目的探讨重组人血管内皮抑制素(恩度)联合化疗方案治疗非小细胞肺癌(NSCLC)的疗效与毒副反应。方法选择NSCLC患者58例,随机分为观察组与对照组各29例,观察组给予恩度联合常规化疗,对照组给予单纯常规化疗,比较两组患者治疗效果与毒副反应。结果所有患者均完成2个周期以上,两组患者近期疗效比较无统计学差异(P>0.05);观察组1年总生存率(58.6%)与1年内肿瘤无进展生存率(20.7%)均显著高于对照组(27.6%,3.4%)(P<0.05),随访至今,观察组肿瘤无进展生存期(PFS)显著高于对照组(P<0.01);两组毒副反应比较差异无统计学意义(P>0.05)。结论恩度联合化疗方案治疗NSCLC疗效显著且安全性高,且不增加毒副反应发生率。

Objective To discuss the efficacy and safety of rh-endostatin injection （endostar） combined with TP, GP or NP regi- men in patients with non-small cell lung cancer （NSCLC）. Methods 58 patients with NSCLC were randomly divided into the endostar combined with routine chemotherapy group （ observation group, n = 29 ） and the routine chemotherapy group （ control group, n = 29 ）. Re- suits There was no significant differences in the efficacies and the disease control rate between the two groups （ P 〉 0.05 ）. The one-year overall survival time of observation group and control group were 7.2 months and 5.2months, with significant difference （ P 〈 0. 05 ）. The one-year survival rate （58.6%） and tumor progression-free survival rate within one-year （20.7%） in observation group were significantly higher than those in control group （27.6% , 3.4% ） （ P 〈 0. 05 ）. So far, the PFS of observation group was significantly longer than con- trol group（P 〈 0.01 ）. There was no significant difference in the toxicity between the two groups （P 〉 0.05 ）. Conclusion Endostar combined chemotherapy is effective and safe in the treatment of advanced NSCLC, without increasing the toxicities.